Press Releases

2014/2/14

ScinoPharm Reports Financial Performance for 2013

ScinoPharm (TWSE:1789) an active pharmaceutical ingredient (API) specialty company, announced unaudited record results for its fiscal year 2013. The company posted a historically high NT$5.088 billion (US$167.6 million) in revenue,

2013/11/11

Genovate and ScinoPharm Co-Develop Hepatitis B Drug

Genovate Biotechnology Co. Ltd. (4130:TT) and ScinoPharm Taiwan Ltd. (1789:TT) announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B.

2013/9/9

ScinoPharm to Provide Active Pharmaceutical Ingredient for Newly Launched Antiepileptic Drug Trokendi XR™ in the US

ScinoPharm Taiwan Ltd. (TSE: 1789.TW) announced that its Tainan, Taiwan Facility provides commercial manufacturing of topiramate active pharmaceutical ingredient (“API”) for Trokendi XR™, a novel once-daily extended release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals in the U.S. market.